Structure−Activity Relationships of Uridine 5‘-Diphosphate Analogues at the Human P2Y<sub>6</sub> Receptor
作者:Pedro Besada、Dae Hong Shin、Stefano Costanzi、Hyojin Ko、Christophe Mathé、Julien Gagneron、Gilles Gosselin、Savitri Maddileti、T. Kendall Harden、Kenneth A. Jacobson
DOI:10.1021/jm060485n
日期:2006.9.1
been studied. Uridine 5'-diphosphate (UDP) analoguesbearing substitutions of the ribose moiety, the uracil ring, and the diphosphate group were synthesized and assayed for activity at the human P2Y6 receptor. The uracil ring was modified at the 4 position, with the synthesis of 4-substituted-thiouridine 5'-diphosphate analogues, as well as at positions 2, 3, and 5. The effect of modifications at the
Hitherto unknown nucleoside analogues incorporating the fivenaturallyoccurringnucleicacidbases built on a 2-oxabicyclo[3.1.0]hexane template were synthesized. The synthesis of these new conformationally restricted nucleoside analogues involved the preparation of a suitable sugar precursor bearing the 2-oxabicyclo[3.1.0]hexane scaffold. This sugar was readily obtained from [(3aS,6aS)-2,2-dimethyl-3a
合成了迄今为止的未知核苷类似物,所述类似物结合了在2-氧杂双环[3.1.0]己烷模板上构建的五个天然存在的核酸碱基。这些新的构象受限的核苷类似物的合成涉及制备带有2-氧杂双环[3.1.0]己烷骨架的合适的糖前体。这种糖很容易从[(3a S,6a S)-2,2-二甲基-3a,6a-二氢呋喃[2,3- d ] [1,3]二氧戊-5-基]甲基苄基醚(4)中获得。继Simons-Smith型环丙烷化反应之后。最后,糖基化反应和脱保护提供了核苷类似物。使用核苷14以胸腺嘧啶碱基为模型,我们发现这种核苷类似物的构象被限制为0 T 1构象。
Synthesis and Conformational Analysis of C-4′-Modified (2-Oxabicyclo[3.1.0]hexyl)pyrimidine Nucleosides
We report on the synthesis of hitherto unknown pyrimidinenucleoside analogues bearing the 2-oxabicyclo[3.1.0]hexane scaffold (5, 6, 8, 13–17 and 19) with various modifications at the C-4′ position including methylene, azido, and arabino-like configuration. Conformationalanalysis on the nucleoside analogues 6, 14 and 17 indicates that the conformation of such C-4′-modifiednucleoside analogues was restricted
Hitherto unknown restricted 3′-deoxy-3′,4′-exo-methylene nucleoside derivatives bearing the nucleicacidnaturallyoccurring pyrimidine bases have been synthesized. The compounds were tested for their activity against HIV, HBV, and several RNA viruses, but they did not show significant antiviral effect.